Peptidify
← Back to the journal
EVIDENCE AUDITJuly 24, 2026 · 5 min read

The two lives of GHK-Cu: why the serum and the vial are different products

One molecule, sold as a face cream and as an injectable vial, gets discussed as if they were the same thing. The evidence bases could not be more different.

A molecule with a real résumé

GHK-Cu — glycyl-histidyl-lysine bound to copper — is not a marketing invention. It is an endogenous human plasma tripeptide, discovered in 1973, with decades of legitimate research: wound healing, skin remodeling, gene-expression modulation in cell studies. Its plasma concentration declines with age, which is the seed of every longevity claim attached to it. That résumé is exactly why it deserves a precise audit instead of either hype or dismissal.

Life one: the cosmetic

In creams, GHK-Cu sits in the cosmetic-peptide middle class: real basic science, weak-to-modest human cosmetic trials, heavy dependence on formulation. The molecule is small enough to have plausible skin penetration in the right vehicle, but the published human evidence for visible anti-aging effect is thin and largely industry-adjacent. Cosmeceutical, not pharmaceutical — and priced accordingly, which is fair.

Life two: the vial

Injectable GHK-Cu is where the conversation leaves the data. The transition from topical cosmetic to subcutaneous injection is a change of product category, not just route: injected peptides bypass the skin barrier entirely, reach systemic circulation, and carry injectable-specific risks — sterility, endotoxin contamination, aggregation — that creams simply do not have. No registered human trial has tested injectable GHK-Cu for skin quality, hair growth or systemic anti-aging. The community protocols circulating online are extrapolations from cell culture and the cosmetic literature, which is an evidence category error.

The copper question

One under-discussed point: GHK-Cu is a copper-delivery vehicle. Deliberately raising systemic copper exposure through repeated injection is a pharmacology decision with no dosing framework behind it. Copper homeostasis is tightly regulated; chronic supraphysiologic exposure is not benign in the way a moisturizer is. Nobody has studied where that line sits for injectable GHK-Cu, because nobody has properly studied injectable GHK-Cu at all.

How to hold both lives in your head

The codex splits them on purpose: topical GHK-Cu is a cosmetic ingredient with modest evidence and low risk; injectable GHK-Cu is a research chemical with enthusiastic anecdotes and a short safety ledger. Same sequence, different risk classes. Most bad GHK-Cu takes — both pro and con — come from blending the two.

The takeaway

  • 01GHK-Cu is a real endogenous peptide with legitimate wound-healing and remodeling research behind it.
  • 02Topical cosmetic evidence: modest and formulation-dependent. Injectable evidence for any outcome: no registered human trials.
  • 03Injection introduces sterility and dosing risks a cream doesn't carry — plus deliberate copper exposure with no studied framework.
  • 04Same molecule, two risk classes: judge the serum and the vial separately.

Verdict — WATCH

The science is real; the injectable extrapolation is not. The serum is a cosmetic, the vial is an experiment.

References

  1. Pickart L, Margolina A. GHK-Cu biology and aging literature (reviewed in codex).
  2. GHK-Cu monograph — Peptidify codex.